12 February 2011 in The Oncologist
Anemia in cancer patients can be treated with transfusions, and 15% of patients with solid tumors are being treated by transfusions. Different cutoff values are used for transfusions, depending on clinical symptoms and patient characteristics, with a hemoglobin (Hb) level of <9 g/dL most commonly used. After the administration of one unit of red blood cells (RBC), the Hb rises with 1 g/dL, and the life span of transfused RBC is 100–110 days. Complications related to RBC transfusion are procedural problems, iron overload, viral and bacterial infections, and immune injury. RBC transfusions have been related to increased risk of the development of non-Hodgkin lymphoma and chronic lymphocytic leukemia, and are related to a worse treatment outcome in selected cancers. In addition, the cost of a transfusion for the patient and society is around 300–500 euros per unit transfused. RBC transfusions should be used carefully to correct anemia in patients with cancer.
1 September 2010 in The Cancer Journal
Palliative care emergencies are emergencies in patients with an incurable disease that may lead to death or decreased quality of life. During the palliative care phase of a patient's life, they differ from other medical emergencies and are mainly focusing on symptom control, whereas disease-oriented treatments are less important. Palliative care emergencies can occur on the physical, emotional, and existential field. They involve not only the patient but also the family and sometimes the health care professional. Palliative care emergencies that are addressed are pain, acute dyspnea, major bleeding, acute function loss, acute anxiety, delirium, epileptic seizures, acute decompensation with aggressive behavior of the nonprofessional caregiver, and planning for predictable emergencies.
12 January 2007 in Cancer Treatment Reviews
1 May 2010 in Advances in Therapy
24 November 2005 in Future Oncology
Paclitaxel and docetaxel are cytotoxic agents that act on the microtubule system and cause cell death. They are active in patients with squamous cell carcinoma of the head and neck region. They can be combined with other cytotoxic agents and radiotherapy with acceptable toxicity. This article reviews of both docetaxel and paclitaxel data in this patient population. Taxanes do not yet have a a license for use in the standard treatment of patients with head and neck cancer in Europe.
4 March 2022 in Frontiers in Oncology
The number of elderly patients with incurable head and neck cancer will increase. They are in need of geriatric palliative care, that takes into account oncology, palliative care and geriatric medicine. In this review of the most recent and relevant literature and includes the expert opinion of the authors, several physical problems (e.g. pain, fatigue, malnutrition, and loco-regional problems) encountered by the elderly head and neck cancer patients are addressed. In addition end-of life issues in this patient population are discussed.